Cover Image
市場調查報告書

醫藥品臨床實驗服務的全球市場·產業的未來預測 (2017∼2027年):各類服務 (早期/後期服務),各終端用戶 (製藥企業,生物科技企業等),各治療領域 (癌症,心血管疾病,中樞神經系統,感染疾病,代謝疾病) 其他

Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases

出版商 Visiongain Ltd 商品編碼 209076
出版日期 內容資訊 英文 188 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品臨床實驗服務的全球市場·產業的未來預測 (2017∼2027年):各類服務 (早期/後期服務),各終端用戶 (製藥企業,生物科技企業等),各治療領域 (癌症,心血管疾病,中樞神經系統,感染疾病,代謝疾病) 其他 Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases
出版日期: 2017年07月11日 內容資訊: 英文 188 Pages
簡介

全球醫藥品臨床實驗 (臨床試驗) 服務市場在2016∼2027年間預測將以9.8%的年複合成長率 (CAGR) 增長。

本報告提供全球臨床實驗服務市場相關分析,提供臨床實驗的概略流程,臨床實驗服務市場·企業概要,主要的推動及阻礙市場要素和外性要素,整體市場趨勢預測 (今後11年份),各類服務·各終端用戶·各治療領域 (各疾病)·各地區的詳細趨勢,主要企業簡介,未來性的市場成長機會等相關調查。

第1章 分析概要

第2章 醫藥品臨床實驗服務市場:概要

  • 臨床實驗:歷史性的流程
  • 臨床實驗的設計和實行
  • 臨床實驗的階段
    • 第一階段:初次人體研究
    • 第二階段:概念證明
    • 第三階段:醫藥品的認證申請
    • 醫藥品上市後監測
    • 臨床實驗的關鍵要素
  • 臨床實驗的設計
    • 通過自適應試驗設計改進臨床試驗模型
  • 臨床實驗的外包化
    • 進行臨床試驗中存在的挑戰
    • 外包化的優點

第3章 全球臨床實驗服務市場:各類服務

  • 經濟對臨床試驗服務市場的影響 (今後11年份)
  • 市場規模的預測值:各服務階段 (今後11年份)
    • 初期階段
    • 後期階段
    • 其他

第4章 全球臨床實驗服務市場:各終端用戶

  • 臨床研究委外機構 (CRO)的演進
  • 市場規模的預測值:各終端用戶 (今後11年份)
    • 製藥企業用
    • 生物科技企業用
    • 其他終端用戶

第5章 全球臨床實驗服務市場:各治療領域

  • 主要的治療領域的臨床服務趨勢預測 (今後11年份)
    • 癌症
    • 心血管疾病
    • 中樞神經系統 (CNS) 疾病
    • 感染疾病
    • 代謝疾病
    • 其他

第6章 各地區臨床實驗服務市場預測

  • 北美市場 (今後11年份)
    • 各國:美國等
    • 各類服務
    • 各治療領域
    • 終端用戶
  • 歐洲市場 (今後11年份)
    • 各國:德國,英國,西班牙,義大利,俄羅斯,中東歐等
  • 亞太地區 (今後11年份)
    • 各國:中國,印度,日本,韓國等
  • 其他的國? (RoW)的市場 (今後11年份)
    • 各國:中東·非洲各國,巴西等

第7章 推動及阻礙市場要素

  • 未來的推動及阻礙市場要素
  • 推動市場要素
    • 生物醫藥品企業的研究開發 (R&D) 擴大,促使臨床實驗服務的活用
    • 臨床研究委外機構 (CRO):新興國家市場上今後的成長的架子
    • 由於生物醫藥品企業的研究開發 (R&D) 擴大,臨床實驗市場活性化
    • 新興國家 (特別是中國):是日益流行的臨床實驗據點
    • 跟大生物醫藥品企業和CRO的策略性聯盟擴大,市場優勢
  • 阻礙市場要素
    • 法規限制 (臨床試驗的批准時間更長等)
    • 醫生·護士的參加者不足,患者參加率低迷

第8章 臨床實驗服務市場主要企業

  • Quintiles IMS Holdings Inc.
    • 產業概要
    • 主要的財務指標
    • 企業策略
  • LabCorp (Covance Inc.)
  • Pharmaceutical Product Development (PPD), LLC
  • Parexel International Corporation
  • ICON
  • INC Research
  • inVentiv Health
  • PRA Health Sciences
  • Chiltern International
  • Charles River Laboratories

第9章 臨床實驗服務市場STEP分析 (今後11年份)

  • STEP分析與
  • 社會要素和臨床實驗的影響
    • 進行臨床試驗的倫理考量
    • 臨床實驗患者募集:先進國家市場主要的課題
  • 技術性要素和臨床實驗的影響
    • 電子式臨床實驗工具
    • 利用電子病歷 (EHR)迅速募集患者
    • 多中心式臨床實驗用工具的雲端運算
  • 經濟要素和臨床實驗的影響
    • 製藥企業研究開發 (R&D) 策略的調整
    • 對民間投資者來說,更富有魅力的CRO
  • 政治要素和臨床實驗的影響
    • 認證後的醫藥品的安全性和臨床試驗
    • 放鬆管制·手續簡單化

第10章 結論

附錄

圖表一覽

分析對象企業的一覽 (全202公司)

分析對象團體的一覽 (全43團體)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0210

Title:
PHARMA CLINICAL TRIAL SERVICES MARKET AND INDUSTRY FORECAST 2017-2027
Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases.

The pharma clinical trial services market is expected to grow at a CAGR of 9.5% in the first half of the forecast period. The market is expected to grow at a CAGR of 9.8% from 2016-2027. The pharma clinical trial services market is estimated at $39.56bn in 2016 dominated by the late-phase services, which held 56% of share.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 188-page report you will receive 145 charts - all unavailable elsewhere.

The 188-page report provides clear detailed insight into the pharma clinical trial services market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Pharma Clinical Trial Services Market forecasts from 2017-2027
  • This report breaks down the revenue forecast for pharma clinical trial services market by type of service:
  • Early Phase Services
  • Late Phase Services
  • Other Services

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

  • This report breaks down the revenue forecast for pharma clinical trial services market by End-Users:
    • Pharma
    • Biotech Companies
    • Other End-Users

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

  • This report breaks down the revenue forecast for pharma clinical trial services market by Therapeutic Area:
    • Cancer
    • Cardiovascular
    • CNS
    • Infectious Diseases
    • Metabolic Diseases
    • Other Diseases

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • North America: the US and Rest of North America
    • Europe: France, Germany, the UK, Spain, Italy, Russia, Central and Eastern Europe, Rest of Europe
    • Asia-Pacific: China, India, Japan, South Korea, Rest of APAC
    • Rest of the World: Latin America, Middle East and Africa, Brazil

Each regional market is further divided by type of service, end-users and therapeutic area.

  • Our study discusses factors that drive and restrain the pharma clinical trial services market. This report also provides a STEP analysis
  • This report discusses the leading companies in pharma clinical trial services market:
    • Quintiles IMS Holdings Inc.
    • LabCorp (Covance Inc.)
    • Pharmaceutical Product Development (PPD), LLC
    • Parexel International Corporation
    • ICON
    • INC Research
    • inVentiv Health
    • PRA Health Sciences
    • Chiltern International
    • Charles River Laboratories

Visiongain's study is intended for anyone requiring commercial analyses for the pharma clinical trial services market. You find data, trends and predictions.

Buy our report today Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pharma Clinical Trial Services Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Structure of the Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Pharma Clinical Trial Services Market Introduction

  • 2.1. Clinical Trials: A Historical Perspective
  • 2.2. Design and Execution of Clinical Trials
  • 2.3. Phases of Clinical Trials
    • 2.3.1. Phase I Trials: First In-Human Studies
    • 2.3.2. Phase II Trials: Proof-of- Concept
    • 2.3.3. Phase III Trials: Drug Approval Applications
    • 2.3.4. Post-Marketing Studies
    • 2.3.5. Key Elements of Clinical Trials
  • 2.4. Common Trial Designs
    • 2.4.1. Improving Clinical Trial Models through Adaptive Trial Designs
  • 2.5. Clinical Trial Outsourcing
    • 2.5.1. Challenges Exist in Conducting Clinical Trials
    • 2.5.2. Benefits of Outsourcing

3. Pharma Clinical Trial Services: World Market by Services 2016-2027

  • 3.1. The Impact of Economy on the Clinical Trial Services Market 2017-2027
  • 3.2. Pharma Clinical Trial Services Market by Services 2017-2027
    • 3.2.1. Early Phase Clinical Trial Services Market Forecasts 2017-2027
    • 3.2.2. Late Phase Clinical Trial Services Market Forecasts 2017-2027
    • 3.2.3. Other Clinical Trial Services Market Forecasts 2017-2027

4. Pharma Clinical Trial Services: World Market by End-Users 2016-2027

  • 4.1. The Evolution of the Clinical Research Organizations (CROs)
  • 4.2. Pharma Clinical Trial Services Market by End-Users 2017-2027
    • 4.2.1. Clinical Trial Services Market by Pharma End-Users Forecasts 2017-2027
    • 4.2.2. Clinical Trial Services Market by Biotech Companies End-Users Forecasts 2017-2027
    • 4.2.3. Clinical Trial Services Market by Other End-Users Forecasts 2017-2027

5. Pharma Clinical Trial Services: World Market by Therapeutic Areas 2017-2027

  • 5.1. Rise of Clinical Trial Services in Key Therapeutic Areas
    • 5.1.1. Cancer Clinical Trial Services Market Forecasts 2017-2027
    • 5.1.2. Cardiovascular Diseases Clinical Trial Services Market Forecasts 2017-2027
    • 5.1.3. CNS Diseases Clinical Trial Services Market Forecasts 2017-2027
    • 5.1.4. Infectious Diseases Clinical Trial Services Market Forecasts 2017-2027
    • 5.1.5. Metabolic Diseases Clinical Trial Services Market Forecasts 2017-2027
    • 5.1.6. Other Diseases Clinical Trial Services Market Forecasts 2017-2027

6. Regional Pharma Clinical Trial Services Market Forecasts 2017-2027

  • 6.1. North American Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.1.1. U.S. Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.1.2. Rest of North America Pharma Clinical Trial Services Market Forecasts 2017-2027
  • 6.2. North American Pharma Clinical Trial Services Market Forecasts by Service 2017-2027
  • 6.3. North American Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2017-2027
  • 6.4. North American Pharma Clinical Trial Services Market Forecasts by End-Users 2017-2027
  • 6.5. Europe Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.1. France Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.2. Germany Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.3. U.K. Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.4. Spain Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.5. Italy Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.6. Russia Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.7. Central and Eastern Europe Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.5.8. Rest of Europe Pharma Clinical Trial Services Market Forecasts 2017-2027
  • 6.6. European Pharma Clinical Trial Services Market Forecasts by Service 2017-2027
  • 6.7. European Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2017-2027
  • 6.8. European Pharma Clinical Trial Services Market Forecasts by End-Users 2017-2027
  • 6.9. Asia-Pacific Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.9.1. China Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.9.2. India Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.9.3. Japan Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.9.4. South Korea Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.9.5. Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market Forecasts 2017-2027
  • 6.10. Asia-Pacific Pharma Clinical Trial Services Market Forecasts by Service 2017-2027
  • 6.11. Asia-Pacific Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2017-2027
  • 6.12. Asia-Pacific Pharma Clinical Trial Services Market Forecasts by End-Users 2017-2027
  • 6.13. Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.13.1. Latin America Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.13.2. Middle East and Africa Pharma Clinical Trial Services Market Forecasts 2017-2027
    • 6.13.3. Brazil Pharma Clinical Trial Services Market Forecasts 2017-2027
  • 6.14. Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by Service 2017-2027
  • 6.15. Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2017-2027
  • 6.16. Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by End-Users 2017-2027

7. Drivers & Restraints

  • 7.1. Drivers and Restraints 2017-2027
  • 7.2. Drivers
    • 7.2.1. Increased research and development by biopharmaceutical companies leading to better utilization of clinical trial services
    • 7.2.2. Contract research organizations present in the emerging markets to gain major foothold in the forecast period
    • 7.2.3. Growth of biopharma R&D expenditures will lead to increase in the clinical trial market
    • 7.2.4. Emerging markets especially China becoming a much sought-after clinical trial destination
    • 7.2.5. Increased Strategic Alliances among Large BioPharma Companies and CROs benefitting the market
  • 7.3. Restraints
    • 7.3.1. Regulatory Constraints such as longer approval time for clinical trials
    • 7.3.2. Poor Physician and Nurse Engagement Leading to Low Patient Recruitment Rates

8. Leading Companies in the Pharma Clinical Trial Services Market

  • 8.1. Quintiles IMS Holdings Inc.
    • 8.1.1. Quintiles IMS Holdings Inc. Business Overview
    • 8.1.2. Quintiles IMS Holdings Inc. Financial Overview
    • 8.1.3. Quintiles IMS Holdings Inc. Corporate Strategy
  • 8.2. LabCorp (Covance Inc.)
    • 8.2.1. LabCorp Business Overview
    • 8.2.2. LabCorp Financial Overview
    • 8.2.3. LabCorp (Covance Inc.) Corporate Strategy
  • 8.3. Pharmaceutical Product Development (PPD), LLC
    • 8.3.1. Pharmaceutical Product Development (PPD) Business Overview
    • 8.3.2. Pharmaceutical Product Development (PPD) Financial Overview
    • 8.3.3. Pharmaceutical Product Development (PPD) Corporate Strategy
  • 8.4. Parexel International Corporation
    • 8.4.1. Parexel International Corporation Business Overview
    • 8.4.2. Parexel International Corporation Financial Overview
    • 8.4.3. Parexel International Corporation Corporate Strategy
  • 8.5. ICON
    • 8.5.1. ICON Business Overview
    • 8.5.2. ICON Financial Overview
    • 8.5.3. ICON Corporate Strategy
  • 8.6. INC Research
    • 8.6.1. INC Research Business Overview
    • 8.6.2. INC Research Financial Overview
    • 8.6.3. INC Research Corporate Strategy
  • 8.7. inVentiv Health
    • 8.7.1. inVentiv Health Business Overview
    • 8.7.2. inVentiv Health Financial Overview
    • 8.7.3. inVentiv Health Corporate Strategy
  • 8.8. PRA Health Sciences
    • 8.8.1. PRA Health Sciences Business Overview
    • 8.8.2. PRA Health Sciences Financial Overview
    • 8.8.3. PRA Health Sciences Corporate Strategy
  • 8.9. Chiltern International
    • 8.9.1. Chiltern International Business Overview
    • 8.9.2. Chiltern International Financial Overview
    • 8.9.3. Chiltern International Corporate Strategy
  • 8.10. Charles River Laboratories
    • 8.10.1. Charles River Laboratories Business Overview
    • 8.10.2. Charles River Laboratories Financial Overview
    • 8.10.3. Charles River Laboratories Corporate Strategy

9. STEP Analysis of the Pharma Clinical Trial Services Market 2017-2027

  • 9.1. STEP Analysis of the Pharma Clinical Trial Services Market
  • 9.2. Social Factors Affecting Clinical Trials
    • 9.2.1. Ethical Considerations in Conducting Clinical Trials
    • 9.2.2. Patient Recruitment: Major Challenge in Developed Markets
  • 9.3. Technological Development for Improved Trials
    • 9.3.1. Electronic Data Capture
    • 9.3.2. eClinical Trial Tools
    • 9.3.3. Use of Electronic Health Records for Faster Patient Recruitment
    • 9.3.4. Cloud Computing used as a Tool for Multicentre Trials
  • 9.4. Economic Considerations for Clinical Trial Outsourcing
    • 9.4.1. Pharma is adjusting its R&D strategies
    • 9.4.2. CROs tend to be attractive for Private Investigators
  • 9.5. Political and Regulatory Considerations for Clinical Trial Outsourcing
    • 9.5.1. Drug Safety and Clinical Trials Post-Approval
    • 9.5.2. Cutting Red Tape and Other Regulatory Developments

10. Conclusions

  • 10.1. Current Leading Pharma Clinical Trial Services Market Segments
    • 10.1.1. Leading Contract Research Organizations
    • 10.1.2. Leading Regional Markets
    • 10.1.3. Emerging Pharma Clinical Trial Services Markets

Appendices

  • Glossary
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Figures:

  • Figure 2.1: Brief History of Clinical Trials
  • Figure 3.1: Breakdown of Pharma Clinical Spending by Phase
  • Figure 3.2: Global Pharma Clinical Trial Services Market by Services: (% Share), 2016
  • Figure 3.3: Pharma Clinical Trial Services Market by Services: Revenue ($bn), 2016-2027
  • Figure 3.4: Early Phase Services Market Forecasts: AGR (%), 2017-2027
  • Figure 3.5: Global Early Phase Clinical Trial Services Market by Region: Revenue ($bn), 2016-2027
  • Figure 3.6: Global Early Phase Clinical Trial Services Market Share by Region: (% Share), 2016-2027
  • Figure 3.7: Late Phase Clinical Trial Services Market Forecasts: AGR (%), 2017-2027
  • Figure 3.8: Global Late Phase Clinical Trial Services Market by Region: Revenue ($bn), 2016-2027
  • Figure 3.9: Global Late Phase Clinical Trial Services by Region: (% Share), 2016-2027
  • Figure 3.10: Other Pharma Clinical Trial Services Submarket Forecasts: AGR (%), 2017-2027
  • Figure 3.11: Global Other Pharma Clinical Trial Services Market by Region: Revenue ($bn), 2016-2027
  • Figure 3.12: Global Other Pharma Clinical Trial Services by Region: (% Share), 2016-2027
  • Figure 4.1: Pharma Clinical Trial Services Submarkets by End-Users: Revenue ($bn), 2016-2027
  • Figure 4.2: Clinical Trial Services Pharma Submarket: AGR (%), 2017-2027
  • Figure 4.3: Global Clinical Trial Services Pharma Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 4.4: Global Clinical Trial Services Pharma Submarket by Region: (% Share), 2016-2027
  • Figure 4.5: Clinical Trial Services Biotech Companies Submarket: AGR (%), 2017-2027
  • Figure 4.6: Global Clinical Trial Services Biotech Companies Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 4.7: Global Clinical Trial Services Biotech Companies Submarket by Region: (% Share), 2016-2027
  • Figure 4.8: Clinical Trial Services Other End-Users Submarket: AGR (%), 2017-2027
  • Figure 4.9: Global Clinical Trial Services Other End-Users Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 4.10: Global Clinical Trial Services Other End-Users Submarket by Region: (% Share), 2016-2027
  • Figure 5.1: Global Pharma Clinical Trial Services Market by Therapeutic Area: (% Share), 2016
  • Figure 5.2: Pharma Clinical Trial Services Submarkets by Therapeutic Area: Revenue ($bn), 2016-2027
  • Figure 5.3: Cancer Clinical Trial Services Submarket: AGR (%), 2017-2027
  • Figure 5.4: Global Cancer Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.5: Global Cancer Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 5.6: Cardiovascular Diseases Clinical Trial Services Submarket: AGR (%), 2017-2027
  • Figure 5.7: Global Cardiovascular Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.8: Global Cardiovascular Diseases Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 5.9: CNS Diseases Clinical Trial Services Submarket: AGR (%), 2017-2027
  • Figure 5.10: Global CNS Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.11: Global CNS Diseases Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 5.12: Infectious Diseases Clinical Trial Services Submarkets: AGR (%), 2017-2027
  • Figure 5.13: Global Infectious Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.14: Global Infectious Diseases Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 5.15: Metabolic Diseases Clinical Trial Services Submarkets: AGR (%), 2017-2027
  • Figure 5.16: Global Metabolic Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.17: Global Metabolic Diseases Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 5.18: Other Diseases Clinical Trial Services Submarket: AGR (%), 2017-2027
  • Figure 5.19: Global Other Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2016-2027
  • Figure 5.20: Global Other Diseases Clinical Trial Services Submarket by Region: (% Share), 2016-2027
  • Figure 6.1: Regional Pharma Clinical Trial Services Markets: Revenue ($bn), 2017-2027
  • Figure 6.2: North American Pharma Clinical Trial Services by Country: (% Share), 2016
  • Figure 6.3: U.S. Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.4: Rest of North America Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.5: North American Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2016-2027
  • Figure 6.6: North American Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2016-2027
  • Figure 6.7: North American Pharma Clinical Trial Services Market by End-Users: Revenue ($bn), 2016-2027
  • Figure 6.8: European Pharma Clinical Trial Services by Country: (% Share), 2016
  • Figure 6.9: France Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.10: Germany Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.11: U.K. Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.12: Spain Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.13: Italy Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.14: Russia Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.15: Central and Eastern Europe (CEE) Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.16: Rest of Europe Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.17: European Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2016-2027
  • Figure 6.18: European Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2016-2027
  • Figure 6.19: European Pharma Clinical Trial Services Market by End-users: Revenue ($bn), 2016-2027
  • Figure 6.20: Asia-Pacific Pharma Clinical Trial Services Market Share by Country: (% Share), 2016
  • Figure 6.21: China Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.22: India Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.23: Japan Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.24: South Korea Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.25: Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.26: Asia-Pacific Pharma Clinical Trial Services Market Revenue by Service: Revenue ($bn), 2016-2027
  • Figure 6.27: Asia-Pacific Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2016-2027
  • Figure 6.28: Asia-Pacific Pharma Clinical Trial Services Market by End-Users: Revenue ($bn), 2016-2027
  • Figure 6.29: Rest of the World (RoW) Pharma Clinical Trial Services Market by Country (% Share), 2016
  • Figure 6.30: Latin America Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.31: Middle East and Africa Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.32: Brazil Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 6.33: RoW Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2016-2027
  • Figure 6.34: RoW Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2016-2027
  • Figure 6.35: RoW Pharma Clinical Trial Services Market Revenue by End-Users: Revenue ($bn), 2016-2027
  • Figure 7.1: Market: Drivers and Restraints, 2017-2027
  • Figure 8.1: Quintiles IMS Holdings Inc. 2016 Annual Revenue by Business Segment: (% Share)
  • Figure 8.2: LabCorp (Covance Inc.) 2016 Annual Revenue by Business Segments: (% Share)
  • Figure 8.3: LabCorp Annual Revenue 2012-2016 ($bn)
  • Figure 8.4: Pharmaceutical Product Development (PPD) 2010 Annual Revenue by Business Segment (% Share)
  • Figure 8.5: Parexel International Corporation 2016 Annual Revenue by Business Segment (% Share)
  • Figure 8.6: Parexel International Corporation Annual Revenue 2012- 2016 ($mn)
  • Figure 8.7: ICON Annual Revenue 2012- 2016 ($bn)
  • Figure 8.8: INC Research 2016 Annual Revenue by Business Segment: (% Share)
  • Figure 8.9: INC Research Annual Revenue 2012-2016 ($bn)
  • Figure 8.10: PRA Health Sciences 2016 Annual Revenue by Business Segment: (% Share)
  • Figure 8.11: PRA Health Sciences Annual Revenue 2012-2016 ($bn)
  • Figure 8.12: Charles River Laboratories 2016 Annual Revenue by Business Segment: (% Share)
  • Figure 8.13: Charles River Laboratories Annual Revenue 2012-2016 ($bn)
  • Figure 10.1: Global Pharma Clinical Trial Services Market: Revenue ($bn), 2016-2027
  • Figure 10.2: Pharma Clinical Trial Services Market by Region: Revenue ($bn), 2016-2027

List of Tables:

  • Table 2.1: Founding Members of the ICH
  • Table 2.2: Types of Adaptive Trial Design
  • Table 3.1: Breakdown of Pharma Clinical Spending by Phase, 2014
  • Table 3.2: Breakdown of Pharma Clinical Trial Services by Services
  • Table 3.3: Table 3.3 Pharma Clinical Trial Services Market by Services: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 3.4: Table 3.4 Early Phase Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 3.5: Table 3.5 Late Phase Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%) 2016-2027
  • Table 3.6: Other Pharma Clinical Trial Services Markets by Region: Forecast ($bn, AGR%, CAGR%) 2016-2027
  • Table 4.1: Pharma Clinical Trial Services Submarket by End-Users: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.2: Clinical Trial Services Pharma Submarket by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.3: Clinical Trial Services Biotech Companies Submarket by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 4.4: Clinical Trial Services Other End-Users Submarket by Region: Forecasts ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.1: Pharma Clinical Trial Services Submarkets by Therapeutic Area: Forecast ($bn, AGR %, CAGR%), 2016-2027
  • Table 5.2: Cancer Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.3: Cardiovascular Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.4: CNS Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.5: Infectious Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.6: Metabolic Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 5.7: Other Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2016-2027
  • Table 6.1: Regional Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.2: U.S. Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.3: Rest of North America Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.4: North American Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.5: North American Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.6: North American Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.7: France Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.8: Germany Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.9: U.K. Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.10: Spain Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.11: Italy Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.12: Russia Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.13: Central and Eastern Europe (CEE) Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.14: Rest of Europe Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.15: European Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.16: European Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.17: European Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.18: China Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.19: India Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.20: Japan Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.21: South Korea Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.22: Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.23: Asia-Pacific Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.24: Asia-Pacific Pharma Clinical Trial Services Market Forecasts by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.25: Asia-Pacific Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.26: Latin America Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.27: Middle East and Africa Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.28: Brazil Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2016-2027
  • Table 6.29: RoW Pharma Clinical Trial Services Market Forecasts by Service: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.30: RoW Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 6.31: RoW Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2016-2027
  • Table 9.1: STEP Analysis of Pharma Clinical Trial Services Market 2016-2027

Companies Listed:

  • 3C Alliance
  • Actavis
  • Adamas Pharmaceuticals
  • Adheris (an InVentiv Health company)
  • Agilent Technologies
  • Agility Clinical
  • AKESOgen
  • Akos
  • Allscripts
  • Amgen
  • Aptiv Solutions (now part of ICON plc)
  • Aptuit
  • ASAN Medical Center
  • Assent Consulting
  • Astellas Pharma
  • Avista Capital Partners
  • Baxter International
  • Bayer
  • BeijingWits Medical Consulting (part of ICON)
  • Berry Consultants
  • BioBay
  • BioClinica
  • BioDuro (part of PPD)
  • BioDuro Biologics
  • Biogen Idec
  • Biomedical Systems
  • BioTrak
  • Bioxydyn
  • BML
  • Boehringer Ingelheim
  • Bridgepoint Development Capital
  • Bristol-Myers Squibb
  • Caprion
  • Catalent
  • Catalina Health (part of InVentiv Health)
  • Celerion
  • Charles River Laboratories
  • ClinForce
  • Clinical Trial Support
  • Clinigene International
  • Clinipace Worldwide
  • ClinStar
  • CMIC Holdings
  • CMIC (Beijing) Co
  • CNS Healthcare
  • CNS Vital Signs
  • Cogtest (part of The Cognition Group)
  • Corex Pharmaceutical
  • CRI Lifetree (part of PRA Health Sciences)
  • Cromos Pharma
  • CROMSOURCE
  • Cross Country Healthcare Inc
  • Czura Thornton
  • Dako (part of Agilent Technologies)
  • Duke Clinical Research Institute
  • EF Education First
  • Eisai
  • Ekam Imaging
  • Eli Lilly
  • EPS Corporation (now EPS Holdings, Inc.)
  • EPS Holdings, Inc.
  • Firecrest Clinical (part of ICON)
  • Forest Pharmaceuticals
  • Frontage Laboratories
  • GCP ClinPlus
  • GE Healthcare
  • Genstar Capital
  • Global CNS Research
  • Global Research Services (GRS)
  • Glówny Urzad Statystyczny (Polish Central Statistical Office)
  • GSK
  • Harlan Laboratories (part of Huntingdon Life Sciences)
  • Hellman & Friedman
  • Hisun Pharmaceuticals
  • Huntingdon Life Sciences
  • i3 Research (part of inVentiv Health)
  • ICON
  • ImageIQ
  • ImmuneHealth
  • INC Research
  • Infociencia (part of RPS)
  • Inspire
  • Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
  • Integrium
  • inVentiv Health
  • J&J
  • Janssen Pharmaceuticals (a subsidiary of J&J)
  • Japan Pharmaceutical Manufacturers Association (JPMA)
  • Jasper Clinical Research and Development Inc.
  • Java Clinical
  • JCL Bioassay Corporation (part of CMIC Holdings)
  • Julphar
  • Kendle (part of INC Research)
  • Kester Capital
  • Kforce
  • Kforce Clinical Research (KCR, part of inVentiv Health)
  • Kinship Technologies (part of PRA Health Sciences)
  • KKR
  • Korea National Enterprise for Clinical Trials (KoNECT)
  • Kun Tuo (part of Quintiles)
  • Laboratory Corporation of America (LabCorp)
  • Les Entreprises du Médicament (LEEM)
  • LSK Global
  • MAB Discovery
  • Malaysian Biotechnology Corporation
  • Massachusetts General Hospital
  • Maximax Pharmaceutical Research
  • MDS Pharma Services (part of INC Research)
  • MedAvante
  • Medaxial
  • Medelis
  • Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
  • Medidata Solutions
  • MediMedia Pharma Solutions (now part of ICON plc)
  • Medipal Holdings
  • Medivation
  • MEK Consulting (part of INC Research)
  • Merck & Co.
  • Merck BioVentures
  • Merck KGaA
  • Metabolon
  • MetricStream
  • Mitsubishi Gas Chemical Company, Inc.
  • Molecular NeuroImaging
  • MorphoSys
  • MPI Research
  • MRM Proteomics
  • Myriad Genetics
  • Mytrus
  • Nautic Partners
  • NeuroImage
  • NextGen Sciences
  • Nexus Oncology, an Ockham Company (formerly Nexus Oncology)
  • Novartis
  • Novotech
  • Ockham
  • OCT
  • Omnicare
  • Oncobiologics
  • Ontario Teachers' Pension Plan
  • Oxford Cancer Biomarkers
  • Oxford Gene Technology (OGT)
  • Oxford Outcomes (part of ICON)
  • Pacific Biomarkers
  • Paragon Biomedical (part of Clinipace Worldwide)
  • Paramax International (part of RPS)
  • Parexel International
  • PatientsLikeMe
  • Perceptive Informatics (part of Parexel)
  • PFC Pharma Focus (part of Clinipace Worldwide)
  • Pfizer
  • PharmaNet Development Group (part of inVentiv Health)
  • Pharmaron
  • PPD
  • PRA International
  • Prana Biotechnology
  • PriceSpective (part of ICON)
  • Prodia Clinical Laboratory
  • Proteome Sciences
  • ProTrials Research
  • PSR Orphan Experts
  • Psychmed (part of The Cognition Group)
  • QED Clinical Services
  • Quintiles
  • Quotient Clinical
  • RCT Logic
  • Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
  • ReSearch Pharmaceutical Services (RPS, part of PRA International)
  • Roche
  • Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
  • Samsung
  • SAS
  • ShangPharma
  • Shire
  • Syngene International
  • Sugi Medical Co (part of CMIC)
  • Taijitu Biologics
  • Targos Molecular Pathology
  • Tessella
  • The Carlyle Group
  • The Clinical Trial Company
  • The Cognition Group
  • Theorem Clinical Research
  • Theradex Systems
  • Therapharm Recherches (part of RPS)
  • Thomas H. Lee Partners
  • Tigermed Consulting
  • Timaq Medical Imaging (part of ICON)
  • Trident Clinical Research (part of INC Research)
  • UCB
  • University of Manchester
  • Veeda Clinical Research
  • Veeva Systems
  • Vigiun (part of Chiltern International)
  • VirtualScopics
  • Warburg Pincus
  • West Coast Clinical Trials (WCCT)
  • Worldwide Clinical Research
  • WuXi AppTec
  • WuXi PharmaTech
  • Yungjin Pharmaceutical
  • Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd

Organizations Mentioned in Report:

  • Administration of Science, Technology and Training (ASST) [Vietnam]
  • Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
  • Agenzia Italiana del Farmaco (AIFA) [Italy]
  • Associação Brasileira de CROs (Abracro)
  • Association for the Accreditation of Human Research Protection Programs (AAHRPP)
  • Association of Clinical Trial Organisations (ACTO) [Russia]
  • Center for Biologics Evaluation and Research (CBER) [US]
  • CenterWatch
  • Central Drugs Standard Control Organization (CDSCO) [India]
  • Center for Drug Evaluation (CDE)
  • China Food and Drug Administration (CFDA)
  • Chinese Ministry of Commerce
  • Council for International Organizations of Medical Sciences (CIOMS)
  • Department of Health [UK]
  • Department of Health and Human Services [US]
  • Drug Controller General of India (DCGI)
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Parliament
  • Food and Drug Administration (US FDA)
  • Hospital Italiano de Buenos Aires
  • Innovative Medicines Initiative (IMI)
  • International Cancer Genome Consortium
  • International Conference of Harmonisation (ICH)
  • Korea Drug Development Fund (KDDF)
  • Korea Food and Drug Administration (KFDA)
  • L'Agence Nationale de Sécurité du Medicament (L'ANSM) [France]
  • Ministry of Health, Labor and Welfare (MHLW, Japan)
  • Ministry of Public Health [Russia]
  • National Cancer Institute (NCI) [US]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • National Taiwan University Hospital (NTUH)
  • NHS Research Scotland (NRS)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Seoul National University Hospital Clinical Trial Center
  • Shanghai Clinical Research Center
  • State Food and Drug Administration (SFDA) [China] (now CFDA)
  • Therapeutic Goods Administration (TGA) [Australia]
  • World Health Organization (WHO)
  • World Heart Foundation
Back to Top